-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OuqI1vog2VzrS8eTSBXrZ7mh1iff1ocbTwc/qgicuFJyelDQIIxPgS5rbWQFaoWM
 6TvMPjYcKLq7MOKRyfAkEw==

<SEC-DOCUMENT>0000946644-04-000026.txt : 20041220
<SEC-HEADER>0000946644-04-000026.hdr.sgml : 20041220
<ACCEPTANCE-DATETIME>20041220160014
ACCESSION NUMBER:		0000946644-04-000026
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041220
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20041220
DATE AS OF CHANGE:		20041220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HEMISPHERX BIOPHARMA INC
		CENTRAL INDEX KEY:			0000946644
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				520845822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13441
		FILM NUMBER:		041214212

	BUSINESS ADDRESS:	
		STREET 1:		1617 JFK BLVD #660
		STREET 2:		ONE PENN CENTER
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2159880080

	MAIL ADDRESS:	
		STREET 1:		1617 JFK BLVD
		STREET 2:		ONE PENN CENTER
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>r8k-122004.txt
<TEXT>
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported)
                                December 20, 2004

                           HEMISPHERX BIOPHARMA, INC.
             (Exact name of registrant as specified in its charter)


                           Delaware 0-27072 52-0845822
               (state or other juris- (Commission (I.R.S. Employer
           diction of incorporation) File Number) (Identification No.)


              1617 JFK Boulevard, Philadelphia, Pennsylvania 19103
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (215) 988-0080


          (Former name or former address, if changed since last report)


ITEM 5.           OTHER EVENTS AND REGULATION FD DISCLOSURE


     As agreed with the  Company at the outset of  becoming a  director,  having
served for a period of 1 year,  Dr.  Antoni  Esteve has resigned as a director.
Dr.  Esteve  will  continue  to meet with top  management  of the  Company on an
ongoing basis with regard to its developmental  drug Ampligen,  with particular
focus on the HIV/HCV  clinical trial using Ampligen being conducted in Spain by
Laboratorios del Dr. Esteve, S.A. in collaboration with the Company.


<PAGE>
                                                    SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                                HEMISPHERX BIOPHARMA, INC.


December 20, 2004                           By: /s/William A. Carter
                                               ----------------------------
                                               William A. Carter, M.D.,
                                               President


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----